Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.
[esophageal squamous cell carcinoma]
microRNA-
133
a
(
miR-
133
a
)
and
miR-
133
b
,
located
on
chromosome
18
in
the
same
bicistronic
unit
,
have
been
commonly
identified
as
being
downregulated
in
esophageal
squamous
cell
carcinoma
(
ESCC
)
.
The
aim
of
this
study
was
to
investigate
the
correlation
of
miR-
133
a
/
b
expression
with
efficacy
of
paclitaxel-based
chemotherapy
and
clinical
outcome
of
ESCC
patients
.
miR-
133
a
expression
and
miR-
133
b
expression
were
examined
in
100
newly
diagnosed
ESCC
patients
prior
to
treatment
by
quantitative
real-time
PCR
.
Then
,
the
patients
received
four
cycles
of
paclitaxel-based
chemotherapy
,
the
short
-term
treatment
efficacy
was
evaluated
,
and
a
3
-
year
follow-up
was
performed
.
Expression
levels
of
miR-
133
a
and
miR-
133
b
were
both
significantly
lower
in
ESCC
tissues
compared
to
adjacent
noncancerous
tissues
(
both
P
<
0
.
001
)
.
In
addition
,
combined
miR-
133
a
/
b
downregulation
was
found
to
be
closely
correlated
with
advanced
tumor
stage
(
P
=
0
.
02
)
and
poor
differentiation
(
P
=
0
.
01
)
.
Moreover
,
the
response
rate
of
ESCC
patients
to
paclitaxel-based
chemotherapy
was
significantly
higher
in
combined
miR-
133
a
/
b
downregulation
group
compared
with
other
groups
(
P
=
0
.
02
)
.
Furthermore
,
univariate
and
multivariate
Cox
analyses
revealed
that
tumor
stage
and
combined
expression
of
miR-
133
a
/
b
were
independent
prognosis
factors
in
ESCC
patients
.
Our
data
offer
the
convincing
evidence
that
combined
expression
of
miR-
133
a
and
miR-
133
b
may
predict
chemosensitivity
of
patients
with
ESCC
undergoing
paclitaxel-based
chemotherapy
,
implying
its
importance
in
applying
'
personalized
cancer
medicine
'
in
the
clinical
treatment
of
ESCC
.
We
also
identified
combined
expression
of
miR-
133
a
and
miR-
133
b
as
an
effective
prognostic
marker
of
this
malignancy
.
Diseases
Validation
Diseases presenting
"cancer"
symptom
achondroplasia
acute rheumatic fever
adrenal incidentaloma
alpha-thalassemia
benign recurrent intrahepatic cholestasis
cadasil
canavan disease
carcinoma of the gallbladder
cholangiocarcinoma
coats disease
congenital adrenal hyperplasia
congenital diaphragmatic hernia
cowden syndrome
cushing syndrome
cutaneous mastocytosis
dedifferentiated liposarcoma
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
erdheim-chester disease
erythropoietic protoporphyria
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
familial hypocalciuric hypercalcemia
familial mediterranean fever
gm1 gangliosidosis
heparin-induced thrombocytopenia
hereditary cerebral hemorrhage with amyloidosis
hirschsprung disease
hodgkin lymphoma, classical
inclusion body myositis
junctional epidermolysis bullosa
kabuki syndrome
kallmann syndrome
kindler syndrome
lamellar ichthyosis
liposarcoma
locked-in syndrome
lymphangioleiomyomatosis
monosomy 21
neuralgic amyotrophy
oculocutaneous albinism
oligodontia
oral submucous fibrosis
papillon-lefèvre syndrome
pendred syndrome
pleomorphic liposarcoma
primary effusion lymphoma
proteus syndrome
pyomyositis
pyruvate dehydrogenase deficiency
severe combined immunodeficiency
sneddon syndrome
systemic capillary leak syndrome
triple a syndrome
von hippel-lindau disease
waldenström macroglobulinemia
well-differentiated liposarcoma
werner syndrome
wiskott-aldrich syndrome
wolf-hirschhorn syndrome
x-linked adrenoleukodystrophy
This symptom has already been validated
